Today’s Late-Breaking Clinical Trials will have five presentations on the latest research in pulmonary, critical care and sleep medicine.
Today’s “Late-Breaking Clinical Trials” session will cover the latest research findings in the areas of asthma, obstructive sleep apnea, critical illness, lung cancer and idiopathic pulmonary fibrosis.
According to Marc Moss, M.D., chair of the ATS International Conference Committee, the topics to be covered in the session span all aspects of pulmonary, critical care and sleep medicine.
“This is one-stop shopping for our attendees,” Dr. Moss said. “This session will not focus on any one disease or section of these specialties, but instead will cast a wide net. I think that the goal of the late-breaking session is to allow attendees at ATS to hear about the most recent science that is going on in these fields, science that has the potential to change the way we deliver care and the way we manage our patients.”
Dr. Moss said that the ATS brought back this session for the second year because it was so well received and well attended in 2009.
“That’s why we’re continuing it; people want to hear about the newest, leading-edge science out there, and this is a forum that provides it for them,” he said. “This program is full of unpublished research that you
cannot get anywhere else.”
The 2010 session will provide the latest information on the use of bosentan or sildenafil for the treatment of idiopathic pulmonary fibrosis; the role of H1N1 vaccination in patients with severe and mild asthma; the latest data on the use of continuous positive airway pressure (CPAP) on cardiovascular outcomes in non-sleepy patients with obstructive sleep apnea syndrome; and the use of neuromuscular blocking agent therapy for patients with early severe acute respiratory distress syndrome (ARDS).
The Program
- William W. Busse, M.D., a professor of medicine at the University of Wisconsin, Madison, will present “Efficacy And Safety Of Omalizumab in Patients With Moderate-Severe Persistent Asthma Poorly Controlled on High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists: Results of a Phase 111b Randomized Controlled Trial.”
- Ferran Barbé Illa, M.D., of the Istitut de Recerca de Lleida Biomédica in Spain, will present “CPAP and Cardiovascular Outcomes in Non-Sleepy OSAS Patients;”
- Laurent Papazian, M.D., Ph.D., of Sainte-Marguerite University Hospital in Marseille, France, will present “Two-Day Neuromuscular Blocking Agent Therapy in Early Severe ARDS;”
- Robert L. Keith, M.D., associate professor of medicine at the University of Colorado in Denver, will present “Oral Iloprost for the Chemoprevention of Lung Cancer;”
- Talmadge E. King, Jr., M.D., professor of medicine at the University of California, San Francisco, will present “The Build-3 Trial: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study of Bosentan in Idiopathic Pulmonary Fibrosis;” and
- David. A. Zisman, M.D., of the Sansum Clinic in Santa Barbara, California, will present “The Step-IPF Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis.”
C91: “Late-Breaking Clinical Trials” will be presented from 1:30 to 4:30 p.m. today in La Nouvelle Orleans A, on the second level of the Morial Convention Center